What is Oxox … … ... ... ... ... ... ... … … … … … … ?

Oxaliplatin Ebewe

Active Ingredient:: Oxaliplatin
Origin:: EU

Oxaliplatin Ebewe (Oxaliplatin)

Oxaliplatin, the active ingredient in Oxaliplatin Ebewe, is a platinum‑based chemotherapy agent presented as a sterile solution for intravenous infusion use. It is employed in the treatment of colorectal cancer, typically in adult patients. GNH India supplies Oxaliplatin Ebewe as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres and hospitals worldwide.

GNH India supplies Oxaliplatin Ebewe as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres and hospitals worldwide.

Manufacturer / TM Owner

Ebewe Pharma

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Oxaliplatin Ebewe is a platinum‑based chemotherapeutic that acts on the colorectal cancer treatment pathway.

Colorectal cancer: improves survival when combined with fluoropyrimidine‑based regimens.
Gastric cancer: used in combination protocols for advanced disease.
Pancreatic cancer: incorporated into multi‑drug regimens for selected patients.
Ovarian cancer: employed off‑label in certain combination therapies.
Small‑cell lung cancer: used experimentally within clinical trial settings.
Metastatic disease: part of combination regimens to reduce tumor burden.

How It Works

Oxaliplatin forms reactive platinum‑DNA adducts that cause intra‑strand and inter‑strand cross‑links, disrupting DNA replication and transcription. This interference triggers cell‑cycle arrest and apoptosis, particularly in rapidly dividing tumor cells, while sparing most normal tissues at therapeutic doses.

Side Effects

Oxaliplatin Ebewe may cause a range of adverse reactions during and after infusion.

Common Side Effects

Nausea: mild to moderate gastrointestinal upset.
Peripheral neuropathy: tingling or numbness, often dose‑related.
Fatigue: generalized tiredness.
Diarrhoea: loose stools, may require supportive care.
Thrombocytopenia: reduced platelet count.
Elevated liver enzymes: transient increase in hepatic markers.

Serious or Rare Side Effects

Severe hypersensitivity reactions: anaphylaxis or bronchospasm.
Acute neurotoxicity: sudden onset of muscle cramps or spasms.
Hemolytic‑uremic syndrome: rare renal complications.
Severe neutropenia: heightened infection risk.
Cardiotoxicity: rare arrhythmias or myocardial injury.
Persistent peripheral neuropathy: long‑term sensory deficits.

Precautions & Warnings

When handling Oxaliplatin Ebewe, clinicians should observe standard oncology safety protocols.

Renal function monitoring: assess creatinine clearance before each cycle.
Hepatic function monitoring: check liver enzymes regularly.
Neuropathy assessment: evaluate sensory changes before and during therapy.
Hematologic monitoring: perform complete blood counts frequently.
Pregnancy avoidance: contraindicated in pregnant patients; use effective contraception.
Store at below 25°C: keep in original packaging, protect from light and moisture.

Avoid Interactions

Oxaliplatin Ebewe can interact with several concomitant medications, requiring careful management.

Major Interactions (Avoid)

Aminoglycoside antibiotics: increase risk of ototoxicity.
High‑dose vitamin C: may reduce platinum‑DNA binding efficacy.
Live vaccines: immunosuppression may diminish vaccine response.

Moderate Interactions (Monitor Closely)

Anticoagulants: heightened bleeding risk due to thrombocytopenia.\n- NSAIDs: may exacerbate renal toxicity.
CYP450 inducers: potential alteration of drug clearance.
Proton pump inhibitors: possible impact on gastrointestinal tolerance.
Diuretics: may affect electrolyte balance during therapy.

Frequently Asked Questions

Oxaliplatin … … … … … … … … … … … … … …

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 09 Oct 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.